SmartestCrowd
Organizations
Orgs
No organizations
Projects
No projects
0
0
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS | Biogen - Biogen
4/25/23 at 7:07pm
Organization
Biogen.com
44 words
0
Comments
The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.
Business & Industrial
Neurological Conditions
FDA
QALSODYTM
Biogen Inc
SOD1
First Treatment
stockholders
Amyotrophic Lateral Sclerosis
Target
Scientific Advancement
You are the first to view
https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-qalsodytm-tofersen-sod1-als
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...